Co-Diagnostics, Inc. to Present at Sidoti Summer Small Cap Virtual Conference
06/15/2022 - 09:30 AM
SALT LAKE CITY June 15, 2022 Dwight Egan , CEO, Brian Brown , CFO, and Andrew Benson , Head of Investor Relations, will present and host one-on-one meetings with investors at the Sidoti Summer Small Cap Virtual Investor Conference June 15-16, 2022 .
The presentation will begin at 3:15 p.m. EDT on Wednesday June 15, 2022, and can be accessed on the Events and Webcasts section of the Co-Diagnostics website. To register for the presentation or one-on-ones, please visit www.sidoti.com/events .
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-sidoti-summer-small-cap-virtual-conference-301568436.html
SOURCE Co-Diagnostics
CODX Rankings
#5113 Ranked by Stock Gains
CODX Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Salt Lake City
About CODX
co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are
